Home New GI Biomarker Study
New GI Biomarker Study
Wednesday, 25 January 2012 20:07

Biomarker Development for Clinical Diagnosis of Disease Stage and response to Treatment in Inflammatory Bowel Diseases


You are being invited to take part in a research study that is trying to identify biomarkers (proteins in the blood) that would help to diagnose Inflammatory Bowel Disease (IBD) and to help determine the severity of the disease. This study is being conducted at British Columbia’s Children Hospital by Dr. Kevan Jacobson, who has received funding from the Genome BC CDRD Development Fund. 


IBD is a group of chronic intestinal (gut) diseases (it does not go away nor does it have a cure at present) characterized by inflammation (irritation) in the bowel. The most common types of IBD are Ulcerative Colitis and Crohn's Disease. 

Currently IBD is diagnosed using a number of tests: blood tests, colonoscopy (using a flexible tube to see the inside of you gut), biopsies (the removal of a tiny sample of your gut to examine in the lab), MRI (scan of the body), x-rays or ultrasound (another way of seeing inside of the body), and reviewing the medical history. 

A biomarker is a term often used to refer to a protein measured in the blood whose concentration can show if a disease is present and how severe it is. Disease related biomarkers help to show where there is a threat of disease, if a disease already exists, or how such a disease may develop in an individual case.   

The purpose of this pilot study is to identify a reliable biomarker test to help in diagnosing and prediction of the severity of IBD that could ultimately lead to future treatments of IBD. This study will test for different biomarkers using techniques called quantitative mass spectrometry and HPLC which can identify the composition of biomarkers.


A total of 80 children 7-17 years of age, who have been recently diagnosed with IBD not yet started on therapy or within the first 2 weeks of initiation of a 5-ASA compound, will be recruited to the study.

If you agree to take part in this study you will  be asked about your health history and have one blood sample (6.5mL or about 1.5 teaspoons) taken to test for biomarkers.


Blood Draw Risks: You may have pain or bruising at the site where the blood will be drawn. Your doctor can put some cream on your arm to stop the discomfort where the needle is inserted. 

There are no direct benefits from being in this study. 

Your involvement is voluntary; the study will not cost you anything.


For more information about this study, please contact: 

Terry Viczko
Research Coordinator
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Phone: 604-875-2345 Ext. 5312
Fax: 604-875-3244 Attn: Terry Viczko